MA-SECURE-CODE-WARRIOR
24.3.2021 03:25:11 CET | Business Wire | Press release
New research from Secure Code Warrior ® , the global secure coding company, has revealed an attitudinal shift in the software development industry, with organisations bucking traditional practices for DevOps and Secure DevOps.
The global survey of professional developers and their managers found seven in 10 organisations (70%) recognise the importance of secure coding practices, with results indicating an industry-wide shift from reaction to prevention is underway.
Dr. Matias Madou, Chief Technology Officer and Co-Founder at Secure Code Warrior, said, “We are seeing a fundamental shift in mindsets across the world, as the industry slowly moves from reactive, band-aid solutions rolled out after a breach, to the proactive and human-led practice of writing quality software that is intrinsically free from vulnerabilities right from the very first keystroke. ”
“This research shows that ‘secure code’ is becoming synonymous with ‘quality code’ within software development, and security is becoming the responsibility of development teams and leaders—not just AppSec professionals, ” he said.
Secure coding seen as ‘reactive’
Reactive practices like using tools on deployed applications and manually reviewing code for vulnerabilities were the top two practices respondents associated with coding securely. However, a proactive shift in mindset was evidenced across the globe, with more than half (55%) of the developers surveyed also recognising secure coding as the active, ongoing practice of writing software protected from vulnerabilities.
Managers and developers are misaligned
Over half (55%) of managers surveyed said secure coding was practised and integrated throughout the entire development process, compared to only 43% of developers. Conversely, 36% of developers consider secure coding during development but not the design phase, as opposed to under one-third (32%) of managers.
Secure code an increasing indicator of success
While those surveyed identified ‘application performance’ and ‘functionality and features’ as the most common success metrics within software development (67% and 62% respectively), almost four in five (79%) respondents said the importance of ‘secure code’ was growing in prominence.
Application security is shifting
Almost half of respondents (46%) said development leads and teams should be responsible for application security rather than AppSec teams (24%). Over eight in 10 (81%) developers surveyed said they were accountable for any vulnerable code produced.
Developers motivated to upskill
‘Increased productivity and efficiency’, ‘curiosity’ and ‘avoiding problems caused by insecure code’ were identified as the leading intrinsic motivators to learn secure coding (20%, 14% and 11% respectively). Despite only 10% of respondents listing career advancement as a personal motivator, four in five (81%) managers were more likely to hire talent with secure coding skills.
More training is needed
91% of managers surveyed said they faced greater than average difficulty when implementing secure coding practices within their organisation, despite the overwhelming majority of respondents (97%) believing they were sufficiently trained. Perhaps, this is because almost nine in 10 (88%) developers surveyed said coding securely was challenging.
Madou added, “With OWASP’s Top 10 software vulnerabilities causing more security breaches over the past two decades than any others, now is the time for businesses to upskill developers to gain the knowledge and skills needed to stamp out insecure code and prevent issues from occurring in the first place. ”
“Code is at the heart of everyday interactions, and Secure Code Warrior is focused on championing security-skilled developers who can create amazing, safe software for our connected world .”
To gain early access to the report, ‘Shifting from reaction to prevention: The changing face of application security 2021’, register your interest at scw.buzz/earlyaccess
Methodology
Secure Code Warrior® commissioned Evans Data Corporation, the market intelligence leader within the IT industry, to conduct a global survey of developers and decision-makers actively engaged in software development. In August 2020, 400 respondents were surveyed across North America, India, the United Kingdom, Europe, Australia, New Zealand and South-East Asia.
About Secure Code Warrior
Secure Code Warrior is the developer-chosen solution for growing powerful secure coding skills. By making secure coding a positive and engaging experience for developers as they increase their software security skills, our human-led approach uncovers the secure developer inside every coder, helping development teams ship quality code faster.
Through inspiring a global community of security-conscious developers to embrace a preventative secure coding approach, our mission is to pioneer a people-first solution to security upskilling, stamping out poor coding patterns for good. Learn more at securecodewarrior.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323006113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
